J Cell Sci 114:4587–4598PubMed 21. Hayashido Y, Lucas A, Rougeot C, Godyna S, Argraves WS, Rochefort H (1998) Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int J Cancer 75:654–658CrossRefPubMed 22. Qing J,

Maher VM, Tran H, Argraves WS, Dunstan RW, McCormick JJ (1997) Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene 15:2159–2168CrossRefPubMed 23. Greene LM, Twal WO, Duffy MJ et al (2003) Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer 88:871–878CrossRefPubMed 24. Bardin A, Moll F, Margueron R et al (2005) Transcriptional and posttranscriptional selleck screening library regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 146:760–768CrossRefPubMed 25. Moll F, Katsaros D, Lazennec G et al (2002) Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 21:1097–1107CrossRefPubMed 26. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA (2000) Concurrent and independent genetic alterations in the stromal and epithelial cells MDV3100 clinical trial of mammary carcinoma: implications for

tumorigenesis. Cancer Res 60:2562–2566PubMed 27. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP,

Eng C (2002) Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32:355–357CrossRefPubMed 28. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C (2001) Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 10:1907–1913CrossRefPubMed 29. Kunz-Schughart LA, Knuechel R (2002) Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 17:599–621PubMed 30. Kunz-Schughart LA, Knuechel R (2002) Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol 17:623–637PubMed Dolutegravir concentration 31. Yu H, Maurer F, Medcalf RL (2002) Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 99:2810–2818CrossRefPubMed 32. Ranson M, Tian Z, Andronicos NM, Rizvi S, Allen BJ (2002) In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (www.selleckchem.com/products/incb28060.html alpha-PAI-2) on human breast cancer cells. Breast Cancer Res Treat 71:149–159CrossRefPubMed 33. Allen BJ, Tian Z, Rizvi SM, Li Y, Ranson M (2003) Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Br J Cancer 88:944–950CrossRefPubMed 34.